Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

6.8K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
6.8K
Overview of Fatty Acid Metabolism01:28

Overview of Fatty Acid Metabolism

25.3K
Lipids also are sources of energy that power cellular processes. Like carbohydrates, lipids are composed of carbon, hydrogen, and oxygen, but these atoms are arranged differently. Most lipids are nonpolar and hydrophobic. Major types include fats and oils, waxes, phospholipids, and steroids.
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
25.3K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

271
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

319
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
319
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

377
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
377
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

21
Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
21

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The diagnosis and management of portal hypertension in cirrhosis: The Gastroenterological Society of Australia consensus.

Hepatology communications·2026
Same author

A Novel Fibroblast Activation Protein-Based Algorithm to Assess Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease.

Journal of gastroenterology and hepatology·2026
Same author

The IC3 trial: protocol for a multicentre individually randomised controlled trial to compare a cirrhosis detection and hepatocellular carcinoma surveillance pathway vs usual care in Australian general practice for 45-75 years old with risk factors for chronic liver disease.

Trials·2025
Same author

Assessment of metabolic dysfunction-associated fatty liver disease in primary care: a consensus statement summary.

The Medical journal of Australia·2025
Same author

Predicting Hepatic Decompensation in Patients With Metabolic Dysfunction Associated Steatotic Liver Disease-Related Cirrhosis: The ABID-LSM Model.

Alimentary pharmacology & therapeutics·2025
Same author

Hepatocellular Carcinoma and Health-Related Quality of Life: A Systematic Review of Outcomes From Systemic Therapies.

International journal of hepatology·2025

Related Experiment Video

Updated: Apr 24, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

1.2K

Metabolic dysfunction-associated fatty liver disease: an update.

Richard O'Halloran1,2,3,4,5, Leon A Adams1,2,3,4,5, Gary Deed1,2,3,4,5

  • 1Sir Charles Gairdner Hospital, Perth.

Australian Prescriber
|April 23, 2026
PubMed
Summary
This summary is machine-generated.

Metabolic dysfunction-associated fatty liver disease (MAFLD) impacts many Australians and requires primary care attention. Early assessment and management are crucial for preventing severe liver conditions like cirrhosis and cancer.

Keywords:
MAFLDcirrhosisfatty livermetabolic dysfunction–associated fatty liver diseasemetabolic syndromeobesitytype 2 diabetes

More Related Videos

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.9K
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

15.9K

Related Experiment Videos

Last Updated: Apr 24, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

1.2K
Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.9K
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

15.9K

Area of Science:

  • Hepatology
  • Public Health
  • Metabolic Diseases

Background:

  • Metabolic dysfunction-associated fatty liver disease (MAFLD) is a prevalent condition affecting one in three Australian adults.
  • It is an increasingly recognized cause of severe liver disease, including cirrhosis, hepatocellular carcinoma, and liver transplantation.
  • Primary care settings play a vital role in addressing the growing burden of MAFLD.

Purpose of the Study:

  • To highlight the significance of primary care in the prevention, diagnosis, and management of MAFLD.
  • To emphasize the need for assessing adults with metabolic risk factors for MAFLD.
  • To outline recommended diagnostic and management strategies for MAFLD.

Main Methods:

  • Assessment of adults with obesity, type 2 diabetes, or other metabolic risk factors for MAFLD.
  • Utilizing liver ultrasound as the recommended first-line diagnostic test for hepatic steatosis.
  • Implementing noninvasive testing for liver fibrosis and hepatocellular carcinoma surveillance in at-risk individuals.

Main Results:

  • MAFLD affects a significant portion of the Australian adult population.
  • Early identification and intervention in primary care can mitigate progression to advanced liver disease.
  • A multi-faceted management approach is effective in addressing MAFLD and its complications.

Conclusions:

  • Primary care providers are essential in managing MAFLD, a growing public health concern.
  • Screening individuals with metabolic risk factors and utilizing appropriate diagnostic tools are key.
  • Comprehensive management, including fibrosis assessment and surveillance, is crucial for improving patient outcomes and preventing liver disease progression.